Evaluation and management of adolescents with abnormal uterine bleeding

Pediatric Annals

Volumn 44, Issue 9, 2015, Pages e218-e222

  Kowalczyk Mullins, Tanya L ^a   Miller, Rachel J ^b,c   Mullins, Eric S ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Childrens Hospitals and Clinics of Minnesota   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; DESMOPRESSIN; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE DERIVATIVE; TRANEXAMIC ACID; VON WILLEBRAND FACTOR; ANTIFIBRINOLYTIC AGENT;

ADOLESCENT; ANEMIA; ANOVULATION; DIZZINESS; EPISTAXIS; FEMALE; HIRSUTISM; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; HYSTERECTOMY; INTRAUTERINE BALLOON; MENORRHAGIA; MICROCYTIC ANEMIA; PALLOR; PETECHIA; REVIEW; TACHYCARDIA; THYROID DISEASE; UTERUS BLEEDING; DISEASE MANAGEMENT; UTERINE HEMORRHAGE;

ADOLESCENT; ANTIFIBRINOLYTIC AGENTS; CONTRACEPTIVES, ORAL, HORMONAL; DISEASE MANAGEMENT; FEMALE; HUMANS; UTERINE HEMORRHAGE;

EID: 84946920170     PISSN: 00904481     EISSN: 19382359     Source Type: Journal    
DOI: 10.3928/00904481-20150910-09     Document Type: Review

References (41)

1. Munro MG, Critchley HO, Broder MS, Fraser IS; FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113(1):3-13.
2. Committee on Practice Bulletins—Gynecology. Practice bulletin no. 128: diagnosis of abnormal uterine bleeding in reproductive-aged women. Obstet Gynecol. 2012;120(1):197-206.
3. American Academy of Pediatrics Committee on Adolescence; American College of Obstetricians Gynecologists Committee on Adolescent Health Care. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Pediatrics. 2006;118(5):2245-2250.
4. Warner PE, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD. Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. Am J Obstet Gynecol. 2004;190(5):1216-1223.
5. Mitan LAP, Slap GB. Dysfunctional uterine bleeding. In: Neinstein LS, Gordon CM, Katzman DK, Rosen DS, Woods ER, eds. Adolescent Health Care: A Practical Guide. 5th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2007.
6. Shankar M, Lee CA, Sabin CA, Economides DL, Kadir RA. von Willebrand disease in women with menorrhagia: a systematic review. BJOG. 2004;111(7):734-740.
7. Vo KT, Grooms L, Klima J, Holland-Hall C, O’Brien SH. Menstrual bleeding patterns and prevalence of bleeding disorders in a multidisciplinary adolescent haematology clinic. Haemophilia. 2013;19(1):71-75.
8. Byams VR, Kouides PA, Kulkarni R, et al. Surveillance of female patients with inherited bleeding disorders in United States Haemophilia Treatment Centres. Haemophilia. 2011;17 Suppl 1:6-13.
9. Sun GH, Auger KA, Aliu O, Patrick SW, DeMonner S, Davis MM. Posttonsillectomy hemorrhage in children with von Willebrand disease or hemophilia. JAMA Otolaryngol Head Neck Surg. 2013;139(3):245-249.
10. Liu G, Wang Y, Zhang X, Yuan B, Han C, Xue F. Endometrial carcinoma in a 15-year-old obese patient with persistent uterine bleeding. Gynecol Endocrinol. 2014;30(4):277-279.
11. American College of Obstetricians Gynecologists. ACOG committee opinion no. 557: Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Obstet Gynecol. 2013;121(4):891-896.
12. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood. 1987;69(2):454-459.
13. Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993;123(6):893-898.
14. Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103-2114.
15. Hayward CP, Harrison P, Cattaneo M, et al. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost. 2006;4(2):312-319.
16. Philipp CS, Miller CH, Faiz A, et al. Screening women with menorrhagia for underlying bleeding disorders: the utility of the platelet function analyser and bleeding time. Haemo philia. 2005;11(5):497-503.
17. Gresele P; Subcommittee on Platelet Physiology. Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH. J Thromb Haemost. 2015;13(2):314-322.
18. Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14(2):171-232.
19. Santos M, Hendry D, Sangi-Haghpeykar H, Dietrich JE. Retrospective review of norethindrone use in adolescents. J Pediatr Adolesc Gynecol. 2014;27(1):41-44.
20. Munro MG, Mainor N, Basu R, Brisinger M, Barreda L. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial. Obstet Gynecol. 2006;108(4):924-929.
21. Hubacher D, Lopez L, Steiner MJ, Dorflinger L. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons. Contraception. 2009;80(2):113-118.
22. Dilbaz B, Ozdegirmenci O, Caliskan E, Dilbaz S, Haberal A. Effect of etonogestrel implant on serum lipids, liver function tests and hemoglobin levels. Contraception. 2010;81(6):510-514.
23. Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, The Amercian College of Obstetricians Gynecologists. Committee opinion no. 539: adolescents and long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol. 2012;120(4):983-988.
24. Ott MA, Sucato GS; Committee on Adolescence. Contraception for adolescents. Pediatrics. 2014;134(4):e1257-1281.
25. Centers for Disease Control and Prevention (CDC). US Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR Recomm Rep. 2010;59(RR-4):1-86.
26. Bayer Healthcare. Prescribing information for MIRENA (levonorgestrel-releasing intrauterine system); 2014. http://labeling.bayerhealthcare.com/html/products/pi/Mirena_PI.pdf. Accessed August 7, 2015.
27. Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol. 1991;164(3):879-883.
28. Nelson AL. Levonorgestrel intrauterine system: a first-line medical treatment for heavy menstrual bleeding. Womens Health (Lond Engl). 2010;6(3):347-356.
29. James AH, Kouides PA, Abdul-Kadir R, et al. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol. 2009;201(1):12 e11-18.
30. Chi C, Huq FY, Kadir RA. Levonorgestrel-releasing intrauterine system for the management of heavy menstrual bleeding in women with inherited bleeding disorders: long-term follow-up. Contraception. 2011;83(3):242-247.
31. Committee on Adolescent Health Care; Committee on Gynecologic Practice. Committee Opinion No.580: von Willebrand disease in women. Obstet Gynecol. 2013;122(6):1368-1373.
32. Callender ST, Warner GT, Cope E. Treatment of menorrhagia with tranexamic acid. A double-blind trial. Br Med J. 1970;4(5729):214-216.
33. Kouides PA, Byams VR, Philipp CS, et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol. 2009;145(2):212-220.
34. Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116(4):865-875.
35. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands’ diseases. Lancet. 1977;1(8017):869-872.
36. James AH, Kouides PA, Abdul-Kadir R, et al. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol. 2011;158(2):124-134.
37. Hamani Y, Ben-Shachar I, Kalish Y, Porat S. Intrauterine balloon tamponade as a treatment for immune thrombocytopenic purpura-induced severe uterine bleeding. Fertil Steril. 2010;94(7):2769.e13-2769.e15.
38. Baker WD, Soisson AP, Dodson MK. Endometrial cancer in a 14-year-old girl with Cowden syndrome: a case report. J Obstet Gynaecol Res. 2013;39(4):876-878.
39. Committee on Practice Bulletins—Gynecology. Practice bulletin no. 136: management of abnormal uterine bleeding associated with ovulatory dysfunction. Obstet Gynecol. 2013;122(1):176-185.
40. Bowkley CW, Dubel GJ, Haas RA, Soares GM, Ahn SH. Uterine artery embolization for control of life-threatening hemorrhage at menarche: brief report. J Vasc Interv Radiol. 2007;18(1 Pt 1):127-131.
41. Yeasmin S, Nakayama K, Ishibashi M, et al. Microwave endometrial ablation as an alternative to hysterectomy for the emergent control of uterine bleeding in patients who are poor surgical candidates. Arch Gynecol Obstet. 2009;280(2):279-282.